Cue Biopharma cash runway of 14 months raises funding risk
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Cue Biopharma holds US$58m in cash against US$51m annual cash burn, giving roughly 14 months of runway. Operating revenue grew 402% last year, but cash burn rose 72% and equals 50% of market capitalization, raising concerns about capital raising. The article concludes the burn situation poses a risk despite revenue growth, leaving investors exposed to likely dilution.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.